Across TCGA pan-cancer cohorts, DNAH17 Mutation is linked to patient survival in 14 of 34 cancer types, making it a survival-associated DNAH17 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DNAH17 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DNAH17 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.
LUAD, UCEC, and THYM are the cancer types where DNAH17 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.